Legend Biotech Jumps 6% on First-Ever Quarterly Profit and Q2 Revenue Beat

Key Facts

In a move reflecting the successful commercial ramp-up of its therapy portfolio, Legend Biotech recorded a historic shift toward profitability during the second quarter of 2026. According to reports, the company's shares rose 6% to reach $21.88 following the announcement of financial results that exceeded analyst estimates. This marks the first quarter in the company's history of achieving company-wide profitability, driven by robust revenue growth and advancements in its clinical programs.

Financial data shows the company booked a net income of $33.2 million compared to a loss a year earlier, while total revenue surged 52% to $387.5 million, beating the $362.81 million estimate. Reduced unrealized foreign exchange losses also cushioned the bottom line. Within the sector context, analysts note that this performance strengthens the company's position in the CAR-T therapy market, particularly with CARVYKTI sales growing 50% year-over-year.

While updated real-time price data is currently unavailable, the upward trend reflects investor confidence in the company's strong cash position of $965 million and lack of long-term debt. Traders in the US market are currently monitoring macroeconomic data affecting the growth sector, noting that the ISM Services PMI released on August 5, 2026, stood at 54.1, indicating continued expansion in service-oriented sectors including biotechnology.